Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer

References

• American Cancer Society. Cancer Facts & Figures 2014. Georgia, US: American Cancer Society, 2014 http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index. Accessed April 5, 2016
   Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the U.S.: 2010-2020. J Natl Cancer Inst 2011;103:117-28
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al; for the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010;376:1147-54
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;365:1995-2005
   Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138-48
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33
   PubMed Web of Science ®Google Scholar
• Chopra A, Haaland B, Lopes G. Comparative effective analysis between enzalutamide and abiraterone in the treatment of metastatic castration-resistant prostate cancer [abstract]. J Clin Oncol 2013;31(6 Suppl):abstr 217
   Google Scholar
• Li T, Thompson M, Todd MB, et al. An indirect treatment comparison (ITC) and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy [abstract]. J Clin Oncol 2014;32(4 Suppl):abstr 270
   Web of Science ®Google Scholar
• Ellis LA, McKenzie RS, Senbetta M. Cost considerations for new oral therapies for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. Poster presented at the 24th International Prostate Cancer Update; February 19-22, 2014; Vail, CO
   Google Scholar
• Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014;66:815-25
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152-60
   PubMed Web of Science ®Google Scholar
• ZYTIGA® [package insert]. Hornsham, PA: Janssen Biotech, Inc., 2015
   Google Scholar
• XTANDI® [package insert]. Northbrook, IL: Astellas Pharma US, Inc., 2015
   Google Scholar
• Beer TM, Sternberg CN, Higano CS, et al. Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castration-resistant prostate cancer (mCRPC): final analysis of the phase 3 PREVAIL study. Poster presented at the 2015 ASCO Annual Meeting, Chicago, IL
   Google Scholar
• First DataBank. Drug Pricing Policy. California, US: First Databank, 2015 http://www.fdbhealth.com/policies/drug-pricing-policy/. Accessed February 13, 2015
   Google Scholar
• Uno H, Wittes J, Fu H, et al. Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies. Ann Intern Med 2015;163:127-34
   PubMed Web of Science ®Google Scholar
• Spruance SL, Reid JE, Grace M, et al. Hazard ratio in clinical trials. Antimicrob Agents Chemother 2004;48:2787-92
   PubMed Web of Science ®Google Scholar
• Pilon D, Ellis L, Xiao Y, et al. Consideration of concomitant medication use in selection of FDA-approved drugs indicated for prostate cancer, Under revision for publication
   Google Scholar
• Wilson L, Tang J, Zhong L, et al. New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions? J Oncol Pharm Practice 2014;20:417-25
   PubMed Web of Science ®Google Scholar
• Ellis LA, Lafeuille M-H, Gozalo L, et al. Treatment sequences and pharmacy costs observed for abiraterone and enzalutmide: considerations for U.S. Payers. Poster presented at the 2015 AMCP’s 27th Annual Meeting & Expo, San Diego, CA
   Google Scholar
• Ellis LA, Pilon D, Lefebvre P. (Budgetary impact analysis of abiraterone acetate plus prednisone (AA + P) versus enzalutamide (ENZ) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Poster presented at the 2015 AVBCC 5th Annual Conference, Washington, DC
   Google Scholar
• Bui C, O’Day K, Flanders S, et al. Budget impact analysis of enzalutamide for the treatment of metastatic castration-resistant prostate cancer from a US payer perspective. Poster presented at the 2015 ISPOR 20th Annual International Meeting, Philadelphia, PA
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar